BACKGROUND: As data on using MammaPrint®, a 70-gene expression profile for molecular subtyping of breast cancer, are limited in Japanese patients, we aimed to determine the gene profiles of Japanese patients using MammaPrint and to investigate its possible clinical application for selecting adjuvant treatments. PATIENTS AND METHODS: 50 women treated surgically at our institution were examined. The MammaPrint results were compared with the St Gallen 2007 and intrinsic subtype risk categorizations. RESULTS: Of 38 cases judged to be at intermediate risk based on the St Gallen 2007 Consensus, 11 (29%) were in the high-risk group based on MammaPrint. 1 of the 30 luminal A-like tumors (3%) was judged as high risk based on MammaPrint results, whereas 7 of the 20 tumors (35%) categorized as luminal B-like or triple negative were in the low-risk group. There have been no recurrences to date in the MammaPrint group, and this is possibly attributable to most of the high-risk patients receiving chemotherapy that had been recommended on the basis of their MammaPrint results. CONCLUSIONS: Our results indicate that MammaPrint is applicable to Japanese patients and that it is of potential value in current clinical practice for devising individualized treatments.
BACKGROUND: As data on using MammaPrint®, a 70-gene expression profile for molecular subtyping of breast cancer, are limited in Japanese patients, we aimed to determine the gene profiles of Japanese patients using MammaPrint and to investigate its possible clinical application for selecting adjuvant treatments. PATIENTS AND METHODS: 50 women treated surgically at our institution were examined. The MammaPrint results were compared with the St Gallen 2007 and intrinsic subtype risk categorizations. RESULTS: Of 38 cases judged to be at intermediate risk based on the St Gallen 2007 Consensus, 11 (29%) were in the high-risk group based on MammaPrint. 1 of the 30 luminal A-like tumors (3%) was judged as high risk based on MammaPrint results, whereas 7 of the 20 tumors (35%) categorized as luminal B-like or triple negative were in the low-risk group. There have been no recurrences to date in the MammaPrint group, and this is possibly attributable to most of the high-risk patients receiving chemotherapy that had been recommended on the basis of their MammaPrint results. CONCLUSIONS: Our results indicate that MammaPrint is applicable to Japanese patients and that it is of potential value in current clinical practice for devising individualized treatments.
Entities:
Keywords:
70-Gene expression profile; Breast cancer; Japanese patients; MammaPrint; Prognosis
Authors: Stella Mook; Marjanka K Schmidt; Giuseppe Viale; Giancarlo Pruneri; Inge Eekhout; Arno Floore; Annuska M Glas; Jan Bogaerts; Fatima Cardoso; Martine J Piccart-Gebhart; Emiel T Rutgers; Laura J Van't Veer Journal: Breast Cancer Res Treat Date: 2008-07-27 Impact factor: 4.872
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Marieke E Straver; Annuska M Glas; Juliane Hannemann; Jelle Wesseling; Marc J van de Vijver; Emiel J Th Rutgers; Marie-Jeanne T F D Vrancken Peeters; Harm van Tinteren; Laura J Van't Veer; Sjoerd Rodenhuis Journal: Breast Cancer Res Treat Date: 2009-02-13 Impact factor: 4.872
Authors: Ben S Wittner; Dennis C Sgroi; Paula D Ryan; Tako J Bruinsma; Annuska M Glas; Anitha Male; Sonika Dahiya; Karleen Habin; Rene Bernards; Daniel A Haber; Laura J Van't Veer; Sridhar Ramaswamy Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Fabrice Andre; Chafika Mazouni; Cornelia Liedtke; Shu-Wan Kau; Debby Frye; Marjorie Green; Ana M Gonzalez-Angulo; W Fraser Symmans; Gabriel N Hortobagyi; Lajos Pusztai Journal: Breast Cancer Res Treat Date: 2007-04-28 Impact factor: 4.872
Authors: Marc Buyse; Sherene Loi; Laura van't Veer; Giuseppe Viale; Mauro Delorenzi; Annuska M Glas; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian Harris; Jan Bogaerts; Patrick Therasse; Arno Floore; Mohamed Amakrane; Fanny Piette; Emiel Rutgers; Christos Sotiriou; Fatima Cardoso; Martine J Piccart Journal: J Natl Cancer Inst Date: 2006-09-06 Impact factor: 13.506
Authors: Stanley P L Leong; Zhen-Zhou Shen; Tse-Jia Liu; Gaurav Agarwal; Tomoo Tajima; Nam-Sun Paik; Kerstin Sandelin; Anna Derossis; Hiram Cody; William D Foulkes Journal: World J Surg Date: 2010-10 Impact factor: 3.352
Authors: Anna A Belanova; Dmitry S Smirnov; Maxim S Makarenko; Mariya M Belousova; Elena V Mashkina; Anzhela A Aleksandrova; Alexander V Soldatov; Peter V Zolotukhin Journal: Genet Mol Biol Date: 2017-05-29 Impact factor: 1.771